{"id":59974,"date":"2026-03-19T14:12:32","date_gmt":"2026-03-19T06:12:32","guid":{"rendered":"https:\/\/flcube.com\/?p=59974"},"modified":"2026-03-19T14:12:34","modified_gmt":"2026-03-19T06:12:34","slug":"walvax-bio-raises-rmb-2-billion-via-private-placement-tengyun-xinwo-bio-to-become-controlling-shareholder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59974","title":{"rendered":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder"},"content":{"rendered":"\n<p><strong>Walvax Biotechnology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300142:SHE\">SHE: 300142<\/a>) has unveiled plans for a <strong>private placement<\/strong> of <strong>207,983,751 shares<\/strong> to <strong>Beijing Tengyun Xinwo Biotechnology Partnership<\/strong>, a <strong>RMB 2.003 billion<\/strong> (\u2248\u202fUS$290 million) capital injection that will transfer <strong>controlling ownership<\/strong> of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Issuer<\/strong><\/td><td>Walvax Biotechnology Co., Ltd. (SHE: 300142)<\/td><\/tr><tr><td><strong>Investor<\/strong><\/td><td>Beijing Tengyun Xinwo Biotechnology Partnership<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Private placement (strategic equity issuance)<\/td><\/tr><tr><td><strong>Shares Issued<\/strong><\/td><td><strong>207,983,751 shares<\/strong><\/td><\/tr><tr><td><strong>Issue Price<\/strong><\/td><td><strong>RMB 9.63<\/strong> per share (\u2248\u202fUS$1.39)<\/td><\/tr><tr><td><strong>Total Proceeds<\/strong><\/td><td><strong>RMB 2.003 billion<\/strong> (\u2248\u202fUS$290 million)<\/td><\/tr><tr><td><strong>Post\u2011Closing Ownership<\/strong><\/td><td>Tengyun Xinwo Bio: <strong>11.51%<\/strong><\/td><\/tr><tr><td><strong>Control Status<\/strong><\/td><td>Tengyun Xinwo Bio becomes <strong>new controlling shareholder<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Pre\u2011Transaction<\/th><th>Post\u2011Transaction Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Ownership Structure<\/strong><\/td><td>Dispersed shareholder base; no single controlling entity<\/td><td>Concentrated control under Tengyun Xinwo Bio \u2013 strategic direction clarity<\/td><\/tr><tr><td><strong>Capital Position<\/strong><\/td><td>Constrained R&amp;D and manufacturing expansion funding<\/td><td><strong>RMB 2 billion<\/strong> fresh capital enables pipeline acceleration and capacity build\u2011out<\/td><\/tr><tr><td><strong>Governance<\/strong><\/td><td>Management\u2011driven decision making<\/td><td>New controlling shareholder influence on board composition and strategic priorities<\/td><\/tr><tr><td><strong>Market Positioning<\/strong><\/td><td>Mid\u2011tier China vaccine player (COVID\u201119, HPV, pneumonia vaccines)<\/td><td>Potential consolidation platform or partnership leverage with Tengyun Xinwo Bio backing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tengyun-xinwo-bio-profile\">Tengyun Xinwo Bio Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Entity Type:<\/strong> Beijing\u2011based biotechnology investment partnership<\/li>\n\n\n\n<li><strong>Strategic Focus:<\/strong> Biotech sector consolidation and growth\u2011stage platform investments<\/li>\n\n\n\n<li><strong>Control Intent:<\/strong> 11.51% stake sufficient for controlling shareholder status under China A\u2011share governance structures (typically 10\u201115% with voting agreements)<\/li>\n\n\n\n<li><strong>Value Creation Thesis:<\/strong> Walvax vaccine platform (mRNA capabilities, manufacturing infrastructure, established distribution) as foundation for regional vaccine market expansion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Vaccine Sector Consolidation:<\/strong> Transaction signals continued private capital interest in vaccine developers post\u2011COVID\u201119 demand normalization; Walvax&#8217;s mRNA platform (COVID\u201119, RSV, influenza pipeline) and established GMP manufacturing attractive to strategic investors seeking biologics infrastructure.<\/li>\n\n\n\n<li><strong>Walvax Pipeline Prioritization:<\/strong> Proceeds likely directed toward <strong>mRNA vaccine portfolio<\/strong> (RSV, seasonal influenza, next\u2011generation COVID\u201119 variants), <strong>HPV vaccine capacity expansion<\/strong>, and <strong>international market registration<\/strong> (WHO prequalification, emerging market approvals); RMB 2 billion funding de\u2011risks clinical\u2011stage programs.<\/li>\n\n\n\n<li><strong>Tengyun Xinwo Bio Strategy:<\/strong> Controlling stake acquisition vs. passive investment indicates active value\u2011creation intent; potential for operational restructuring, management changes, or strategic partnership facilitation (technology licensing, co\u2011development deals).<\/li>\n\n\n\n<li><strong>Valuation Context:<\/strong> RMB 9.63 issue price represents <strong>~15\u201120% discount<\/strong> to recent trading range (implied pre\u2011money valuation RMB 15\u201117 billion); controlling premium justifies pricing for Tengyun Xinwo Bio given strategic influence and platform access.<\/li>\n\n\n\n<li><strong>Sector Precedent:<\/strong> Follows pattern of biotech private placements to state\u2011backed or strategic investors (Wuxi Biologics, Innovent, CSPC); regulatory approval by Shenzhen Stock Exchange and CSRC expected Q2\u2011Q3 2026 with closing targeted H2 2026.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion timelines, strategic direction changes, and capital deployment plans for Walvax Biotechnology. Actual outcomes may differ due to regulatory approval delays, shareholder approval requirements, and market conditions affecting closing certainty.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u6c83\u68ee\u751f\u7269\uff1a2026\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u9884\u6848.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6c83\u68ee\u751f\u7269\uff1a2026\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u9884\u6848.\"><\/object><a id=\"wp-block-file--media-49c9763b-a9ba-42e3-ab8a-1c7a3f479e83\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u6c83\u68ee\u751f\u7269\uff1a2026\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u9884\u6848.pdf\">\u6c83\u68ee\u751f\u7269\uff1a2026\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u9884\u6848<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/\u6c83\u68ee\u751f\u7269\uff1a2026\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u9884\u6848.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-49c9763b-a9ba-42e3-ab8a-1c7a3f479e83\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,1152,332],"class_list":["post-59974","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-she-300142","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59974\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder\" \/>\n<meta property=\"og:description\" content=\"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59974\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-19T06:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T06:12:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder\",\"datePublished\":\"2026-03-19T06:12:32+00:00\",\"dateModified\":\"2026-03-19T06:12:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"SHE: 300142\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59974#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59974\",\"name\":\"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-19T06:12:32+00:00\",\"dateModified\":\"2026-03-19T06:12:34+00:00\",\"description\":\"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59974\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59974#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder - Insight, China&#039;s Pharmaceutical Industry","description":"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59974","og_locale":"en_US","og_type":"article","og_title":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder","og_description":"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.","og_url":"https:\/\/flcube.com\/?p=59974","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-19T06:12:32+00:00","article_modified_time":"2026-03-19T06:12:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59974#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59974"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder","datePublished":"2026-03-19T06:12:32+00:00","dateModified":"2026-03-19T06:12:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59974"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","SHE: 300142","Walvax Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59974#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59974","url":"https:\/\/flcube.com\/?p=59974","name":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-19T06:12:32+00:00","dateModified":"2026-03-19T06:12:34+00:00","description":"Walvax Biotechnology Co., Ltd. (SHE: 300142) has unveiled plans for a private placement of 207,983,751 shares to Beijing Tengyun Xinwo Biotechnology Partnership, a RMB 2.003 billion (\u2248\u202fUS$290 million) capital injection that will transfer controlling ownership of the China\u2011based vaccine developer to the Beijing\u2011based biotech investment vehicle.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59974#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59974"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59974#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Walvax Bio Raises RMB 2 Billion via Private Placement \u2013 Tengyun Xinwo Bio to Become Controlling Shareholder"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59974"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59974\/revisions"}],"predecessor-version":[{"id":59978,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59974\/revisions\/59978"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}